SpyGlass Pharma appoints Elizabeth O’Farrell to board of directors

ALISO VIEJO, Calif. - SpyGlass Pharma, a privately held ophthalmic biotechnology company, announced Tuesday the appointment of Elizabeth O’Farrell to its Board of Directors as an Independent Director and Chair of the Audit Committee.

O’Farrell brings over 30 years of industry experience in strategic planning, financial optimization, regulatory compliance and management. She spent most of her career at Eli Lilly, where she held several executive positions including General Auditor, CFO of Lilly USA, and SVP of Policy and Finance. Before retiring from Eli Lilly in 2017, she served as Chief Procurement Officer and Head of Global Shared Services.

"Liz’s established track record in large, commercial healthcare organizations with deep experience in global finance and operations will be instrumental as we continue to advance our SpyGlass Drug Delivery Platform into two pivotal Phase 3 trials this year," said Patrick Mooney, Chief Executive Officer of SpyGlass Pharma, in a press release statement.

Currently, O’Farrell serves as a board member and Audit Committee Chair for Karius Inc., Lensar Inc. (NASDAQ:LNSR) and Geron Corporation (NASDAQ:GERN), where she also serves as Chair of the Board. According to InvestingPro data, GERN maintains a strong financial position with a current ratio of 7.87x, indicating robust liquidity. The company’s market capitalization stands at $922 million, though it faces challenges with rapid cash burn despite holding more cash than debt. Additionally, she is a board member and member of the audit and compensation committee of Genmab Corporation (NASDAQ:GMAB).

SpyGlass Pharma is developing a drug delivery platform designed to deliver bimatoprost to targeted tissues for up to three years. The company has completed enrollment in a Phase I/II study in the United States and plans to initiate two pivotal Phase 3 trials for patients with moderate open-angle glaucoma or ocular hypertension.

O’Farrell holds an M.B.A. in Management Information Systems and a B.A. in Accounting from Indiana University Bloomington. For investors interested in deeper analysis of companies like GERN, InvestingPro offers comprehensive research reports covering 1,400+ US stocks, including detailed financial health scores, Fair Value assessments, and expert insights. GERN’s stock currently shows significant potential based on analyst targets, with the stock trading below its InvestingPro Fair Value.

In other recent news, Geron Corporation announced its second-quarter 2025 earnings, reporting an earnings per share (EPS) of -$0.02, which exceeded the forecasted -$0.03. The company’s revenue also surpassed expectations, reaching $49 million compared to the projected $47.81 million. These results highlight Geron’s ability to outperform analyst estimates in both earnings and revenue. The company’s recent financial performance has been a focal point for investors and analysts alike. While the earnings call did not include any information on mergers or acquisitions, the strong earnings report may influence future analyst assessments. No recent analyst upgrades or downgrades were noted in connection with these earnings results. These developments reflect Geron’s current financial trajectory as observed in the recent earnings announcement.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.